Abstract A017: Substance use disorder prevalence among cancer survivors in the United States: A nationally representative analysis
TL;DR
The findings highlight the need for cancer-type-specific SUD screening and underscore the importance of examining psychosocial and treatment-related pathways driving substance use disparities in this population.
Abstract
Cancer survivors represent a growing and medically complex population in the U.S. Substance use disorders (SUDs) are an underrecognized comorbidity in this population, yet population-level data on SUD prevalence across cancer types remain limited. This study estimated the weighted prevalence of SUDs across 17 cancer types among U.S. cancer survivors and examined cancer type as a predictor of any SUD among women. This is a cross-sectional analysis of data from the combined 2021–2024 National Survey on Drug Use and Health (NSDUH) Public Use File. The analytic sample included adults aged 18 years and older with a self-reported lifetime cancer diagnosis. SUD outcomes were defined using DSM-5 recoded variables and included past-year any SUD, alcohol, cannabis, opioid, stimulant, sedative, and other SUDs. Weighted proportions of sociodemographic characteristics and SUD prevalence estimates were calculated using NSDUH-specified survey design parameters. Among women, a survey-weighted logistic regression examined the association between cancer type and any SUD. The analytic sample included 7612 adult cancer survivors (56.49% were female and 57.64% were aged 65 years or older). Overall, 9.91% (95% CI: 8.64, 11.18) of cancer survivors met criteria for any past-year SUD. Alcohol use disorder was the most prevalent disorder (7.40%; 95% CI: 6.19, 8.60), followed by cannabis use disorder (2.30%; 95% CI: 1.84, 2.76). Opioid, stimulant, sedative, and other SUDs were each present in less than 1% of cancer survivors overall. Substantial variation in SUD prevalence was observed across cancer types. The highest prevalence of any SUD was observed among survivors of cervical cancer (19.02%), other cancer types (15.28%), and thyroid cancer (13.14%). In contrast, ovarian cancer survivors had the lowest prevalence of any SUD (2.60%; 95% CI: 0.09, 5.11). Alcohol use disorder was the predominant SUD across nearly all cancer types, with notably high estimates observed among cervical (11.16%), thyroid (10.75%), and bladder (10.09%) cancer survivors. Cervical cancer survivors had the highest prevalence of opioid (3.99%) and stimulant (2.49%) SUDs compared to other cancer types. In the logistic regression among women, after controlling for age, race/ethnicity, marital status, education, family income, insurance status, and survey year, a history of ovarian cancer was significantly associated with lower odds of any past-year SUD compared to women with no cancer history (aOR: 0.25; 95% CI: 0.09, 0.68). Women with a history of cervical cancer demonstrated higher odds of any past-year SUD (aOR: 1.75; 95% CI: 1.01, 3.02). In this nationally representative analysis, approximately 1 in 10 U.S. cancer survivors met criteria for a past-year SUD, with marked variation by cancer type. These findings highlight the need for cancer-type-specific SUD screening and underscore the importance of examining psychosocial and treatment-related pathways driving substance use disparities in this population. Sarah O'Shea, Ana Tergas. Substance use disorder prevalence among cancer survivors in the United States: A nationally representative analysis [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr A017.